WEBULL
WebtradeDownload

Ionis Pharmaceuticals (IONS) On Mixed Trial And FDA News While The Undervalued Narrative Holds

Simply Wall St · 2d ago

Ionis Pharmaceuticals (IONS) is back in focus after mixed trial and regulatory headlines. Partner Novartis reported that the pelacarsen Lp(a)HORIZON Phase 3 trial did not meet its primary endpoint, while Ionis secured FDA approval for rare disease therapy ZANVASTRO.

At a share price of $54.21, Ionis Pharmaceuticals has seen momentum cool, with the stock down 26.02% on a 90 day share price return and the 1 year total shareholder return also lower, despite multi year total returns still positive.

Scan beyond Ionis Pharmaceuticals and compare how other rare disease and high quality biotechs are setting up on our curated list of 18 high quality undiscovered gems.

Ionis Pharmaceuticals now appears to be a strong rare disease platform whose share price has pulled back significantly. Is that combination of portfolio progress and recent drawdown giving you a fair entry or a value trap?

Most Popular Narrative: 38.4% Undervalued

Ionis Pharmaceuticals is trading at $54.21 against a most-followed narrative fair value of $88.00, which frames the recent selloff as a valuation reset rather than a verdict on the platform.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

Read the complete narrative.

Want to see what kind of revenue ramp and margin swing that story is built on. The narrative leans on aggressive growth, richer profitability and a premium earnings multiple to bridge the gap between $54.21 today and the implied fair value in the years ahead.

Result: Fair Value of $88.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Ionis Pharmaceuticals story leans heavily on successful approvals and launches for Olezarsen and Donidalorsen, while pricing pressure and partner execution remain clear swing factors.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Next Steps

Mixed headlines and a sharp pullback can stir strong views on Ionis Pharmaceuticals, but your view matters more than the crowd’s mood. Act while the information is fresh by reviewing the underlying data, including the 2 key rewards

Ready for more ideas beyond Ionis Pharmaceuticals?

Do not stop your research with Ionis Pharmaceuticals. Fresh opportunities often sit just outside your current watchlist, and the right filter can surface them fast.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.